Drug Profile
QBI 139
Alternative Names: QBI-139Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Quintessence Biosciences
- Class Antineoplastics; Endoribonucleases; Ribonucleases
- Mechanism of Action Ribonuclease stimulants; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 28 Apr 2016 Phase-I development is ongoing in USA
- 28 Apr 2016 QBI 139 is available for licensing as of 28 Apr 2016. http://www.quintbio.com/